Zelnorm Withdrawn from Market
June 20, 2022Merck’s Pneumococcal Vaccine Now Indicated for Children
June 22, 2022June 22, 2022 – Zulresso (brexanolone) has obtained an expanded indication to treat postpartum depression (PPD) in patients who are at least 15 years old.
- In 2019, the FDA approved Zulresso to treat PPD in adults. The drug is administered via intravenous infusion under the supervision of a qualified healthcare professional.
- A full course of treatment requires 60 hours and follows a recommended dosing schedule of:
- 0 to 4 hours: Initiate with a dosage of 30mcg/kg of the patient’s weight per hour.
- 4 to 24 hours: Increase dosage to 60mcg/kg/hour.
- 24 to 52 hours: Increase dosage to 90mcg/kg/hour (or consider a dosage of 60mcg/kg/hour for individuals unable to tolerate 90mcg/kg/hour).
- 52 to 56 hours: Decrease dosage to 60mcg/kg/hour.
- 56 to 60 hours: Decrease dosage to 30mcg/kg/hour.